m6A 在乳腺癌中的表达以及其与临床病理特征、生存预后的关系  

Expression of m6A in breast cancer and its relationship with clinicopathological features,survival and prognosis

作　　者：杨国荣[1] YANG Guo-rong(Department of Breast Oncology,Chenzhou First People's Hospital,Chenzhou 423000,Hunan,China)

机构地区：[1]郴州市第一人民医院乳腺肿瘤内科,湖南郴州423000

出　　处：《医学食疗与健康》2022年第19期166-168,共3页Medical Diet and Health

基　　金：郴州市第一人民医院科研项目“m6A在乳腺癌中的表达以及其与临床病理特征、生存预后的关系”(2020XJ106)。

摘　　要：目的:本研究旨在探讨m6A修饰在乳腺癌中的作用,为乳腺癌的靶向治疗提供新思路;通过探究分析乳腺癌患者同m6A甲基转移酶、去甲基化酶相关性,进而明确m6A调控乳腺癌发生发展的机制。方法:选择时间为2015年1月至2020年12月收治于本院,经两位副高级病理科医师证实、具备完整的临床病例资料且符合入选标准的乳腺癌组织石蜡标本30例,以及其配对癌旁组织30例。应用Trizol提取总RNA,并去除rRNA得到RNA样品。采用m6A试剂盒检测总RNA中的RNA m6A甲基化修饰水平。在检测乳腺癌和RNA去甲基化酶(FTO、ALKBH5)、及RNA甲基转移酶(METTL3、METTL14、WTAP)、癌旁组织中m6A水平时,多选择免疫组化法完成。采用qPCR法检测RNA甲基转移酶与RNA去甲基化酶mRNA表达,并分析其与患者疾病预后的相关性。结果:乳腺癌患者m6A和临床分期、淋巴结是否转移存在相关性,出院后患者有间1个月~3年的生存时间,m6A表达水平和患者的生存时间呈现相关性。结论:通过检测乳腺癌与相应癌旁组织中m6A的胞浆表达水平和胞核表达水平,探讨其在不同分子分型、分期与预后乳腺癌组织中的定位,能够更完善、更精确地明确m6A与乳腺癌发生存在密切关联性,有助于实现肿瘤的精准化治疗和患者预后的有效预测,临床应用价值较佳。Objective:This study aims to explore the role of m6A modification in breast cancer and provide a new idea for the targeted treatment of breast cancer;By exploring and analyzing the correlation between breast cancer patients and m6A methyltransferase and demethylase,we can clarify the mechanism of m6A regulating the occurrence and development of breast cancer.Methods:30 paraffin specimens of breast cancer tissues and 30 paired adjacent tissues were selected and treated in our hospital from January 2015 to December 2020,which were confirmed by two associate senior pathologists,had complete clinical case data and met the inclusion criteria.Total RNA was extracted by Trizol,and RNA samples were obtained by removing rRNA.The m6A methylation modification level of RNA in total RNA was detected by m6A kit.When detecting the level of m6A in breast cancer,RNA demethylase(FTO,alkbh5),RNA methyltransferase(mettl3,mettl14,wtap)and adjacent tissues,multi-choice immunohistochemistry was completed.The expression of RNA methyltransferase and RNA demethylase mRNA was detected by qPCR,and their correlation with the prognosis of patients was analyzed.Results:There was a correlation between m6A and clinical stage and lymph node metastasis in patients with breast cancer.Patients had a survival time of 1 month to 3 years after discharge.The expression level of m6A was correlated with the survival time of patients.Conclusion:by detecting the cytoplasmic and nuclear expression levels of m6A in breast cancer and the corresponding adjacent tissues,and discussing its localization in different molecular typing,staging and prognosis of breast cancer tissues,we can better and more accurately clarify the close relationship between m6A and breast cancer,which is conducive to the accurate treatment of tumors and the effective prediction of patients'prognosis,and has better clinical application value.

关 键 词：N6-甲基腺苷 乳腺癌 预后 RNA m6A修饰 甲基转移酶 

分 类 号：R737.9[医药卫生—肿瘤]